Logo image
Sign in
CON: Therapy for a Patient with Platinum–Resistant/Refractory Ovarian Cancer Should Not Be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
Journal article

CON: Therapy for a Patient with Platinum–Resistant/Refractory Ovarian Cancer Should Not Be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay

John Farley and Michael J. Birrer
Clinical ovarian cancer and other gynecologic malignancies, Vol.1(2), pp.99-103
12/2008

Metrics

1 Record Views

Details